The estimated Net Worth of Carol Moore is at least $2.41 Milione dollars as of 12 March 2024. Ms. Moore owns over 20,619 units of Cerus stock worth over $1,005,777 and over the last 11 years she sold CERS stock worth over $422,515. In addition, she makes $981,744 as Senior Vice President - Regulatory Affairs e Quality and Clinical at Cerus.
Sign up
Ms. Moore CERS stock SEC Form 4 insiders trading
Carol has made over 13 trades of the Cerus stock since 2018, according to the Form 4 filled with the SEC. Most recently she sold 20,619 units of CERS stock worth $41,650 on 12 March 2024.
The largest trade she's ever made was exercising 130,000 units of Cerus stock on 25 June 2020 worth over $270,400. On average, Carol trades about 28,594 units every 79 days since 2014. As of 12 March 2024 she still owns at least 490,623 units of Cerus stock.
You can see the complete history of Ms. Moore stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Carol Moore biography
Carol M. Moore serves as Senior Vice President - Regulatory Affairs, Quality and Clinical of the Company. From April 2008 to February 2013, Ms. Moore was our Vice President, Regulatory Affairs, Quality and Clinical. Prior to joining Cerus, Ms. Moore served in various roles at Bayer Corporation, most recently as Vice President, Worldwide Regulatory Affairs, for over 30 years focusing on the registration and regulatory compliance of Bayer’s biological and biotech products, health policy, and strategic planning. Ms. Moore received her BS in Biological Science from California State University, Hayward.
What is the salary of Carol Moore?
As the Senior Vice President - Regulatory Affairs e Quality and Clinical of Cerus, the total compensation of Carol Moore at Cerus is $981,744. There are 5 executives at Cerus getting paid more, with William Greenman having the highest compensation of $3,270,180.
How old is Carol Moore?
Carol Moore is 70, she's been the Senior Vice President - Regulatory Affairs e Quality and Clinical of Cerus since 2013. There are 2 older and 11 younger executives at Cerus. The oldest executive at Cerus Corp. is Laurence Corash, 76, who is the Chief Scientific Officer.
What's Carol Moore's mailing address?
Carol's mailing address filed with the SEC is C/O CERUS CORPORATION, 1220 CONCORD AVE SUITE 600, CONCORD, CA, 94520.
Insiders trading at Cerus
Over the last 21 years, insiders at Cerus have traded over $5,083,598 worth of Cerus stock and bought 1,382,745 units worth $4,903,526 . The most active insiders traders include William Mariner Greenman, Laurence M Corash e Bruce C Cozadd. On average, Cerus executives and independent directors trade stock every 33 days with the average trade being worth of $90,805. The most recent stock trade was executed by Kevin Dennis Green on 3 September 2024, trading 82,657 units of CERS stock currently worth $178,539.
What does Cerus do?
cerus corporation is a biomedical products company focused on commercializing the intercept blood system to enhance blood safety. the intercept system is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. the nucleic acid targeting mechanism of action enables intercept treatment to inactivate established transfusion threats, such as hepatitis b and c, hiv, west nile virus and bacteria, and is designed to inactivate emerging pathogens such as influenza, malaria and dengue. cerus currently markets and sells the intercept blood system for both platelets and plasma in europe, russia, the middle east and selected countries in other regions around the world. the intercept red blood cell system is in clinical development.
What does Cerus's logo look like?
Complete history of Ms. Moore stock trades at Cerus
Cerus executives and stock owners
Cerus executives and other stock owners filed with the SEC include:
-
William Greenman,
President, Chief Executive Officer, Director -
Vivek Jayaraman,
Chief Operating Officer, Chief Commercial Officer -
Laurence Corash,
Chief Scientific Officer -
Richard Benjamin,
Chief Medical Officer -
Kevin Green,
Chief Financial Officer, Vice President - Finance -
Carol Moore,
Senior Vice President - Regulatory Affairs, Quality and Clinical -
Chrystal Menard,
Chief Legal Officer and General Counsel -
Jami Nachtsheim,
Independent Director -
Daniel Swisher,
Independent Chairman of the Board -
Timothy Anderson,
Independent Director -
Frank Witney,
Independent Director -
Gail Schulze,
Independent Director -
Eric Bjerkholt,
Independent Director -
Timothy Moore,
Independent Director -
Tim Lee,
Investor Relations Director -
William J Dawson,
Chief Financial Officer -
Caspar Jan Hogeboom,
Managing Director Cerus Europe -
Bruce C Cozadd,
Director -
David N Cook,
Vice President, R & D -
Chrystal Jensen,
Chief Legal Officer -
Stephen T Isaacs,
Chief Executive Officer -
Gregory W Schafer,
Chief Financial Officer -
International Inc & Subsidi...,
10% owner -
C Raymond Jr Larkin,
Director -
Bj Cassin,
Director -
Howard G Ervin,
Vice President, Legal Affairs -
Claes Glassell,
Executive Officer and Director -
William R Rohn,
Director -
Dean A. Gregory,
-
Ann Lucena,
Director -
Hua Shan,
Director